Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. 2005.

Natural history of type

1 diabetes. Diabetes. 54(2):25-31.

Berard R. Approach to the child with joint inflammation. Pediatr Clin N Am. 2012;59:245-62.


1. Rund D, Rachmilewitz E. -Thalassemia. N Engl J Med. 2005;353:1135-46.
2. Sofro AS. Molecular pathology of beta thalassemia in Indonesia. South East
Asian J Trop Med Public Health.1995;26:2212214.
3. Cappelini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines
for the Clinical Management of Thalassemia. Edisi ke-2. Cyprus:
Thalassaemia International Federation.2008.p.20-32,106-20.
4. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11-
5. Cao A, Galanello R. Beta-thalassemia. Genetics in Medicine. 2010. p. 61
76.
6. Piomelli S. The management of patients with Cooleys anemia: transfusions
and splenectomy. Semin Hematol. 1995;32(4):2628.
7. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of Deferoxamine in
Preventing Complications of Iron Overload in Patients with Thalassemia
Major. N Engl J Med.1994;331:567-73.
8. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen Ar. Complications of beta
thalassemia major in North America. Blood. 2004;104:34-9.
9. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and
Complications in Patients with Thalassemia Major Treated with Transfusion
and Deferoxamine. Haematologica.2004;89:1187-93.
10. Cohen AR. New Advances in Iron Chelation Therapy. Hematology. 2006;42-
7.
11. Hoffbrand AV, Cohen A, Hershko C. Role of Deferiprone in Chelation
Therapy for Transfusional Iron Overload. Blood. 2003;102(1): 17-24.
12. World Health Organization/ thalassemia International Federation. Joint
meeting on the prevention and control of haemoglobinopathies. Nicosia-
cyprus: World Health Organization/Thalassemia International
Federation,1994:20.
13. Porter JB. Iron Toxicity and Clinical Sequelae. Br J Hematol. 2001; 115: 239-
52.
14. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Thalassemia Clinical
Research Network. Complications of beta-thalassemia major in North
America. Blood. 2004, 104:34-39.
15. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del
Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A,
Cnaan A: Survival and complications in patients with thalassemia major
treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-
1193.
16. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload
associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J
Haematol 2006; 135:574.
17. Vermylen C. What is New in Iron Overload?. Eur J Pediatr 2008; 167: 377-
81.
18. Davis BA, OSulivian C. Jarritt PH, Porter JB. Value of sequential monitoring
of left ventricular ejectioon fraction in the of thalasemia major. Blood 2004;
104:263-9.
19. Arijanty L, Nasar SS. Masalah Nutrisi pada thalassemia. Sari Pediatri.
2003;5: 21-26.
20. Fung EB. Nutritional deficiencies in patients with thalassemia. Annals of the
New York Academy of Sciences. 2010.p. 188-96
21. Khurana A, Katyal S, Marwaha RK. Psychosocial burden in thalassemia.
Indian J Pediatr .2006;73(10):87780.